贵州省固定剂量复合剂治疗新涂阳肺结核病人的可行性研究  

Feasibility research on using Fixed-Dose Combination in tuberculosis treatment programme in Guizhou

作　　者：陈慧娟[1] 马可[1] 杨婕[1] 袁薇[1] 杨德慧[1] 雷世光[1] 李杨[1] 

机构地区：[1]贵州省疾病预防控制中心结核病防治研究所,贵州贵阳550004

出　　处：《现代预防医学》2014年第5期930-932,共3页Modern Preventive Medicine

摘　　要：目的评价抗结核固定剂量复合剂(FDC)治疗新涂阳肺结核患者在贵州省结核病防治规划中的可行性。方法在贵州省6个县采用固定剂量复合剂和抗结核板式组合药分别对189例新涂阳肺结核患者进行治疗,比较其2月末痰涂片阴转率、治愈率及不良反应发生率。结果研究组和对照组患者2月末痰涂片阴转率、治愈率及不良反应发生率差异无统计学意义(P>0.05)。结论采用固定剂量复合剂对新涂阳肺结核患者进行治疗能取得与板式药相当的治疗疗效,在结核病防治规划中值得进一步推广。Objective To evaluate feasibility of treating new smear-positive TB patients with Fixed-Dose Combination （FDC） in tuberculosis treatment programme in Guizhou. Methods Case-control study was conducted in 6 counties in Guizhou, 189 new smear-positive TB patients of case group using FDC, 189 patients of control group using the blister pack. Compared the conversion rate at the end of 2 months, and the treatment outcome and side-effect. Results The conversion rate at the end of 2 months, the treatment outcome and side-effect of case group and control group were not obviously different （P〉0.05）. Conclusion The effect on new smear-positive patients treated with FDC is same as the blister pack. The use of FDC should be further expanded in next step.

关 键 词：肺结核 药物治疗 固定剂量复合剂 

分 类 号：R183[医药卫生—流行病学]